Higher pharmaceutical public expenditure after direct price control: improved access or induced demand? The Colombian case

BACKGROUND: High pharmaceutical expenditure is one of the main concerns for policymakers worldwide. In Colombia, a middle-income country, outpatient prescription represents over 10% of total health expenditure in the mandatory benefits package (POS), and close to 90% in the complementary government...

Descripción completa

Detalles Bibliográficos
Autores principales: Prada, Sergio I., Soto, Victoria E., Andia, Tatiana S., Vaca, Claudia P., Morales, Álvaro A., Márquez, Sergio R., Gaviria, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833155/
https://www.ncbi.nlm.nih.gov/pubmed/29507533
http://dx.doi.org/10.1186/s12962-018-0092-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833155/
https://www.ncbi.nlm.nih.gov/pubmed/29507533
http://dx.doi.org/10.1186/s12962-018-0092-0

Ejemplares similares